Evidence map›Paper›PMID 36235117›Full record

ArticleMolecules (Basel, Switzerland)2022

Engineering Peptide Inhibitors of the HFE-Transferrin Receptor 1 Complex.

Daniela Goncalves Monteiro, Gautam Rishi, Declan M Gorman, Guillaume Burnet, Randy Aliyanto, K Johan Rosengren, David M Frazer, V Nathan Subramaniam, Richard J Clark

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Daniela Goncalves MonteiroSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Gautam RishiCentre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, QLD 4059, Australia.
Declan M GormanSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Guillaume BurnetSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Randy AliyantoSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.
K Johan RosengrenSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-5007-8434
David M FrazerThe QIMR Berghofer Medical Research Institute, 300 Herston Rd, Brisbane, QLD 4006, Australia.
V Nathan SubramaniamCentre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology (QUT), Brisbane, QLD 4059, Australia.
Richard J ClarkSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia.ORCID 0000-0002-6807-5426
The University of Queensland · AUQueensland University of Technology · AUQIMR Berghofer Medical Research Institute · AU

Funding

Australian Research Council FT100100476, FT130100890National Health and Medical Research Council APP1082224, APP1118888
6 · The paper itself

Abstract

The protein HFE (homeostatic iron regulator) is a key regulator of iron metabolism, and mutations in HFE underlie the most frequent form of hereditary haemochromatosis (HH-type I). Studies have shown that HFE interacts with transferrin receptor 1 (TFR1), a homodimeric type II transmembrane glycoprotein that is responsible for the cellular uptake of iron via iron-loaded transferrin (holo-transferrin) binding. It has been hypothesised that the HFE/TFR1 interaction serves as a sensor to the level of iron-loaded transferrin in circulation by means of a competition mechanism between HFE and iron-loaded transferrin association with TFR1. To investigate this, a series of peptides based on the helical binding interface between HFE and TFR1 were generated and shown to significantly interfere with the HFE/TFR1 interaction in an in vitro proximity ligation assay. The helical conformation of one of these peptides, corresponding to the α1 and α2 helices of HFE, was stabilised by the introduction of sidechain lactam "staples", but this did not result in an increase in the ability of the peptide to disrupt the HFE/TFR1 interaction. These peptides inhibitors of the protein-protein interaction between HFE and TFR1 are potentially useful tools for the analysis of the functional role of HFE in the regulation of hepcidin expression.

Indexed as

HemochromatosisHepcidinsHemochromatosis ProteinHistocompatibility Antigens Class IHumansIronLactamsMembrane ProteinsPeptidesReceptors, TransferrinTransferrinHemochromatosis ProteinHepcidinsHFE protein, humanHistocompatibility Antigens Class IIronLactamsMembrane ProteinsPeptidesReceptors, TransferrinTransferrinhepcidinHFEstaplingTFR1

Identifiers

PMID36235117
PMCPMC9570809
OpenAlexW4303958949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.